NDC 49502-450

CIMDUO

Lamivudine And Tenofovir Disoproxil Fumarate

CIMDUO is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Mylan Specialty L.p.. The primary component is Lamivudine; Tenofovir Disoproxil Fumarate.

Product ID49502-450_6e54ea13-a4be-4744-b1d6-e444181c0741
NDC49502-450
Product TypeHuman Prescription Drug
Proprietary NameCIMDUO
Generic NameLamivudine And Tenofovir Disoproxil Fumarate
Dosage FormTablet, Film Coated
Route of AdministrationORAL
Marketing Start Date2018-06-25
Marketing CategoryNDA / NDA
Application NumberNDA022141
Labeler NameMylan Specialty L.P.
Substance NameLAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
Active Ingredient Strength300 mg/1; mg/1
Pharm ClassesHepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleosides [CS],Nucleoside Reverse Transcriptase Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 49502-450-93

1 BOTTLE, PLASTIC in 1 CARTON (49502-450-93) > 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC
Marketing Start Date2018-06-25
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 49502-450-93 [49502045093]

CIMDUO TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA022141
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2018-06-25

Drug Details

Active Ingredients

IngredientStrength
LAMIVUDINE300 mg/1

OpenFDA Data

SPL SET ID:a300f04d-118f-4136-aaf3-ddfd00197f86
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 2003255
  • 2003249
  • Pharmacological Class

    • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleosides [CS]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]

    NDC Crossover Matching brand name "CIMDUO" or generic name "Lamivudine And Tenofovir Disoproxil Fumarate"

    NDCBrand NameGeneric Name
    49502-450CIMDUOLamivudine and Tenofovir Disoproxil Fumarate
    32228-004TEMIXYSlamivudine and tenofovir disoproxil fumarate
    72606-002TEMIXYSlamivudine and tenofovir disoproxil fumarate

    Trademark Results [CIMDUO]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    CIMDUO
    CIMDUO
    87418781 5596590 Live/Registered
    Mylan Pharmaceuticals, Inc
    2017-04-20

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.